Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0029463 (
osteosarcoma
)
16,637
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Cancer incidence has been increasing steadily and is the leading cause of mortality worldwide. Gastric cancer is still most common malignancy in Korea. Cancer initiation and progression are multistep processes involving various growth factors and their ligands. Among these growth factors, we have studied hepatocyte growth factor (HGF), which is associated with cell proliferation and invasion, leading to cancer and metastasis, especially in gastric cancer. We explored the intercellular communication between HGF and other surface membrane receptors in gastric cancer cell lines. Using complimentary deoxyribonucleic acid microarray technology, we found new genes associated with HGF in the stomach cancer cell lines, NUGC-3 and MKN-28, and identified their function within the HGF pathway. The HGF/N-methyl-N'-nitroso-guanidine human
osteosarcoma
transforming gene (c-
MET
) axis interacts with several molecules including E-cadherin, urokinase plasminogen activator, KiSS-1, Jun B, and lipocalin-2. This pathway may affect cell invasion and metastasis or cell apoptosis and is therefore associated with tumorigenesis and metastasis in gastric cancer.
...
PMID:Function of hepatocyte growth factor in gastric cancer proliferation and invasion. 3207 17
Recent clinical trials have shown several multi-target tyrosine kinase inhibitors (TKIs) to be effective in the treatment of
osteosarcoma
. However, these TKIs have a number of targets, and it is yet unclear which of these targets has a key role in
osteosarcoma
treatment. In this review, we first summarize the TKIs that were studied in clinical trials registered on ClinicalTrials.gov. Further, we compare and discuss the targets of these TKIs. We found that TKIs with promising therapeutic effect for
osteosarcoma
include apatinib, cabozantinib, lenvatinib, regorafenib, and sorafenib. The key targets for
osteosarcoma
treatment may include VEGFRs and RET. The receptor tyrosine kinases (RTKs)
MET
, IGF-1R, AXL, PDGFRs, KIT, and FGFRs might be relevant but unimportant targets for
osteosarcoma
treatment. Inhibition of one type of RTK for the treatment of
osteosarcoma
is not effective. It is necessary to inhibit several relevant RTKs simultaneously to achieve a breakthrough in
osteosarcoma
treatment. This review provides comprehensive information on TKI targets relevant in
osteosarcoma
treatment, and it will be useful for further research in this field.
...
PMID:Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target? 3298 34
Sarcomas are frequent in dogs and canine species are excellent animal models for studying the human counterpart. However, osteosarcomas are a rare form of sarcoma with high death rates in humans and dogs. miRNAs are small endogenous RNAs that regulate gene expression post-transcriptionally. The discovery of miRNAs could give a contribute in the diagnosis and prognosis of different types of tumors in animal species, as already in humans. The differentiated expression of miRNAs is a frequent finding in cancers and is related to their pathogenesis in many cases. Most canine and human sarcomas show similar miRNA aberrations. Lower levels of miR-1 and miR-133b in canine
osteosarcoma
tissues were found to increase tumorigenesis through a higher expression of their target genes
MET
and MCL1. The overexpression of miR-9 promotes a metastatic phenotype in canine osteosarcomas and its capacity as a prognostic biomarker for the disease is currently being evaluated. MicroRNAs at the 14q32 locus could be used as prognostic biomarkers, since their decreased expression has been associated with poor prognosis in canine and human osteosarcomas. Furthermore, a decreased expression of miR-34a in
osteosarcoma
tumour cells has been associated with shorter disease-free survival times and its reintroduction as a synthetic prodrug shows good potential as a novel therapeutic target to fight the disease. Circulating miR-214 and miR-126 are significantly increased in a broad-spectrum cancer and have the ability to successfully predict the prognosis of dogs. However, further studies are needed to make the use of miRNAs as biomarkers a common practice.
...
PMID:MicroRNAs as Biomarkers in Canine Osteosarcoma: A New Future? 3300 41
<< Previous
1
2
3
4
5
6
7
8
9
10